On September 16, 2022 Servier reported that it has launched an initiative with California Life Sciences Association (CLSA) to support an early-stage life sciences company developing innovative approaches in the therapeutic areas developed by the Group: oncology; auto-immune diseases ; genetically driven neurodegenerative and movement disorders (Press release, Servier, SEP 16, 2022, View Source [SID1234619606])
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"This collaboration offers a great opportunity for California-based innovators and disruptors in earlier stages to get on the radar of a potential licensing or exit partner by applying to this call," said Sibylle Hauser, executive director of Innovation Services at CLS.
"Our partnerships’ philosophy is about accessing innovative new therapeutic solutions to meet patient needs," said Christophe Thurieau, executive director of Servier Research. "Starting a collaboration with California Life Sciences, a leading life science organization in the US, is definitely inspiring. Networked innovation without barriers is crucial for serving patients’ unmet needs even more effectively and rapidly. Agile methods to accelerate R&D programs are based on synergies and teamwork."
Among the 23 applications, Servier has awarded the Servier FAST Discovery Award to F5 Therapeutics. This start up sets up a technological platform to develop First-in-Class small molecules for the treatment of diseases with high unmet medical need notably in oncology and immunology.
Beyond supporting innovation, this initiative is also the opportunity for Servier, to reinforce its interaction with innovative players in the US and more specifically on the West coast and to set up long term relationships with F5 Therapeutics to boost innovation for the benefit of patients.
*Servier favors open collaboration to accelerate the development of therapeutic solutions for the benefit of patients. Convinced that work and ongoing dialogue between healthcare players is the best framework for rapid innovation focused on patients’ needs, Servier continues to expand and diversify its network of R&D partners.